Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Surpass discontinued

This article was originally published in The Tan Sheet

Executive Summary

Wrigley Healthcare Division will be dissolved after discontinuing sales of its Surpass antacid chewing gum March 28. "Despite its quality, Surpass...has not been able to build broad enough popularity with consumers needed to support a brand long-term," 1Wrigley's Web site notes. Healthcare division, which was created two years ago to support Surpass' launch, will be phased out by May, firm says, with employees rejoining parent company. Wrigley's R&D team will "continue to explore the delivery of functional benefits" through chewing gum, with a focus on indications such as throat and cough relief, dental benefits. Firm has attributed poor Surpass sales to difficulty in convincing consumers to switch from liquid/pill antacid forms to gum (2"The Tan Sheet" March 4, 2002, p. 6)...

You may also be interested in...



Surpass Antacid Gum Marketing Strategy Shift Planned By Wrigley

Wrigley Healthcare is modifying its marketing strategy for Surpass antacid gum to increase consumer trials of the product after its introduction resulted in lower than expected sales

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel